0439 GMT - Healthcare software provider Mach7 Technologies looks well-positioned to meet its annual guidance, according to its bull at Wilsons. Analyst Shane Storey tells clients in a note that the Australia-listed company needs to sign more new accounts in its June quarter, but still forecasts 19% annual growth in full-year contracted annual recurring revenue. That's well within Mach7's guidance of 15%-25%. Mach7 is positioned to sustainably generate operating cashflow from hereon, with its cost-cutting initiatives completed in the March quarter, Storey adds. Wilsons cuts its target price by 15% to A$0.85 and keeps an overweight rating on the stock, which is up 7.8% at A$0.345. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 00:39 ET (04:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。